1903Science
Condensates first observed
Peering through an early microscope, Santiago Ramón y Cajal saw membraneless structures now known to be condensates.
Building on condensate science, from concept to company
1903
2009
June, 2009Science
Tony Hyman Science paper published
Tony Hyman and colleagues describe research in Science that begins to unravel the mysteries of biomolecular condensates.
2018
February, 2018Science
Potential of condensates identified
Phil Sharp identifies condensate biology as a once-in-a-generation opportunity to make transformative new medicines.
August, 2018Company
Company founded
Tony Hyman, Rick Young, and Amir Nashat decide to found company, with Phil Sharp as chair of the SAB.
September, 2018Company
Dewpoint named
Founding team sketches out Dewpoint’s strategy. Suzanne Eaton, a brilliant scientist and partner to Tony Hyman, gives the company its name.
October, 2018Company
US operations begin
2019
January, 2019Company
Series A: $60M
Founding investor Polaris Partners led the equity round, joined by Samsara BioCapital, 6 Dimensions Capital, EcoR1 Capital, Alexandria Venture Investments, and Leaps by Bayer.
March, 2019Company
German operations begin
November, 2019Company
$100M deal with Bayer
Bayer and Dewpoint partner to research new treatments for cardiovascular and gynecological diseases.
2020
July, 2020Company
$305M deal with Merck
Dewpoint forges collaboration with Merck to evaluate novel approach for the treatment of HIV.
September, 2020Company
Series B: $77M
Round led by ARCH Venture Partners, with participation from new investors Maverick Ventures and Bellco Capital, and existing investors Leaps by Bayer, EcoR1 Capital, Polaris Partners, Samsara BioCapital, and Innovation Endeavors.
2021
January, 2021Company
$239M deal with Pfizer
Dewpoint partners with Pfizer to develop potential therapies for a rare form of muscular dystrophy.
March, 2021Company
Volastra and Dewpoint partner
Collaboration will combine Volastra’s expertise in cancer biology with Dewpoint’s platform for targeting condensates to identify drug candidates that can stop metastasis and disease progression.
2022
February, 2022Company
Series C: $150M
Round led by SoftBank Vision Fund 2, along with other new investors General Catalyst, Mubadala Capital, 3E Bioventures, Mirae Asset Capital, and NS Investment. Also joining the round were existing investors Leaps by Bayer, Polaris Partners, Samsara BioCapital, ARCH Venture Partners, EcoR1 Capital, and Maverick Ventures.